Mixed-lineage protein kinase (MLK)

Mixed-lineage protein kinases (MLKs) are a family of serine/threonine protein kinases that function as mitogen-activated protein kinase kinase kinases (MAP3Ks) within the MAPK signaling cascade (UniProt). They are characterized by a unique domain architecture containing a kinase domain with features of both serine/threonine and tyrosine kinases, followed by a leucine zipper and a CRIB domain (PubMed). MLKs primarily activate the c-Jun N-terminal kinase (JNK) and p38 pathways, which are critical for cellular responses to stress, cytokines, and growth factors (NCBI). In pathological states, overactivation of MLKs is associated with neuronal apoptosis in neurodegenerative diseases like Parkinson's and Alzheimer's, as well as promoting tumor progression and metastasis in various cancers (PubMed). Therapeutic development has focused on small-molecule inhibitors like CEP-1347 and URMC-099 to provide neuroprotection and anti-inflammatory effects (NIH). Despite their potential, clinical trials for MLK inhibitors have faced challenges regarding efficacy and the complexity of targeting specific kinase isoforms without systemic toxicity (PubMed).

Other names

Mitogen-activated protein kinase kinase kinase 11MAP3K11MLK3Mitogen-activated protein kinase kinase kinase 9MAP3K9MLK1Mitogen-activated protein kinase kinase kinase 10MAP3K10MLK2Mitogen-activated protein kinase kinase kinase 21MAP3K21MLK4Mixed lineage kinase

Inhibition of the kinase domain to prevent phosphorylation of downstream MAP2Ks (MKK4 and MKK7), thereby blocking the activation of the JNK and p38 MAPK signaling pathways.